Assessment of Minimal Residual Disease in Standard-Risk AML
Authors:
- Adam IveyAIAdam Ivey
- Robert K. HillsRHRobert K. Hills
- Michael A. SimpsonMSMichael A. Simpson
- Jelena V. JovanovicJJJelena V. Jovanovic
- Amanda GilkesAGAmanda Gilkes
- Angela GrechAGAngela Grech
- Yashma PatelYPYashma Patel
- Neesa BhudiaNBNeesa Bhudia
- Hassan FarahHFHassan Farah
- Joanne MasonJMJoanne Mason
- Kerry WallKWKerry Wall
- Susanna AkikiSASusanna Akiki
Top Cited Papers
- 4 February 2016
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 374 (5) , 422-433
Abstract
To the Editor: Ivey and colleagues (Feb. 4 issue)1 tested the prognostic value of the presence of a mutation in the gene encoding nucleophosmin (NPM1) in patients with acute myeloid leukemia (AML) who were in complete hematologic remission after a second cycle of chemotherapy,2 although the recovery of cell counts in peripheral blood was not required for a determination of such remission. Some of the patients were in remission after the first cycle of chemotherapy and some were not. Moreover, some of the patients in remission had normal blood counts and some did not. Other studies have shown . . .Keywords
This publication has 38 references indexed in Scilit:
- Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceBlood, 2016
- Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2015
- Mutational landscape and significance across 12 major cancer typesNature, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachNature Reviews Clinical Oncology, 2012
- Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid LeukemiaJournal of Clinical Oncology, 2012
- DNMT3AMutations in Acute Myeloid LeukemiaNew England Journal of Medicine, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid LeukemiaNew England Journal of Medicine, 2008
- Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal KaryotypeNew England Journal of Medicine, 2005